Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of PRN1008 in moderate-to-severe pemphigus
MOH_2019-03-20_006039Phase 3Completed
- Sponsor
- Principia Biopharma
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pemphigus vulgaris (PV) and pemphigus foliaceus (PF) comparing PRN1008 + background corticosteroids with Placebo + background corticosteroids (2 arms). Primary endpoints: Efficacy of PRN1008 and Safety events related to study drug or background corticosteroids. Started Mar 2019; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on MOH_2019-03-20_006039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-20_006039.